Peer-reviewed article
Real-world ADHD pharmacological treatment patterns and their association with negative clinical outcomes in youth with comorbid autism: a Swedish population-based study.
Garcia-Argibay M, Kuja-Halkola R, D'Onofrio BM, Lichtenstein P, Chang Z et al. ·
Summary
Written by AI, not yet AICS's view · claude-haiku-4-5-20251001This Swedish study examined how children and adolescents with both ADHD and autism spectrum disorder are treated with medications compared to those with ADHD alone. Young people with both conditions experienced longer delays before starting medication treatment and switched medications more frequently. The study found that different ADHD medications had similar effects on reducing negative outcomes like psychiatric hospitalization and injury rates.
Key points
- Children with ADHD and autism were delayed in starting treatment (12-14% waited over 12 months after diagnosis versus 7-8% with ADHD alone)
- Children with both conditions had higher rates of stopping treatment within 3 months (16% vs 12%) and switched medications more often (average 2.6 switches in 3 years)
- Different ADHD medications showed similar effects on reducing psychiatric hospitalization, accidental injuries, and specialist care visits for substance use or mental health problems
- The study included over 24,000 children with ADHD and autism and 79,830 with ADHD alone, tracked from diagnosis through 2021
Limitations
The study describes real-world treatment patterns but cannot establish whether the observed delays and medication switching were clinically appropriate or harmful. The findings on medication comparisons are based on observational data rather than randomized trials, so causation cannot be confirmed.
Abstract
Background Attention-deficit/hyperactivity disorder (ADHD) medications can reduce ADHD symptom severity in individuals with comorbid autism spectrum disorder (ASD). However, clinical guidance on pharmacological treatment of ADHD in this clinical population remains limited and inconsistent. Characterising real-world treatment patterns (ie, initiation timing, medication choices, switching, discontinuation) and the impact of alternative medication choices on clinical outcomes is critical for informing evidence-based management strategies. Objective To (1) characterise ADHD pharmacological treatment patterns in youth with ADHD+ASD versus ADHD alone and (2) assess whether using alternative ADHD medications versus methylphenidate is associated with differential changes in negative clinical outcomes among youth with ADHD+ASD. Methods This is a population-based cohort study using Swedish national registers. The study included children (<13 years) and adolescents (13-17 years) with an incident ADHD diagnosis between 2007 and 2018 and followed-up until 2021, comparing youth with co-occurring ASD (n=24 117) and ADHD alone (n=79 830). Descriptive outcomes included time to pharmacological treatment initiation, medication type, number of medication switches and discontinuations. The primary outcome was changes in rates of inpatient psychiatric hospitalisations, accidental injuries and specialist care visits for substance use, depressive or anxiety disorders in the 1 year after versus the 1 year before medication initiation. Findings Individuals with ADHD+ASD experienced longer delays to treatment initiation (12-14% initiated >12 months after diagnosis vs 7-8% in ADHD alone). Children with ADHD+ASD were slightly more likely to discontinue treatment within 3 months (16% vs 12%) and had the highest average number of medication switches within 3 years (2.6; IQR 0.0-2.0). In within-individual analyses, comparisons of alternative ADHD medications versus methylphenidate did not yield statistically significant differences after correcting for multiple comparisons. Conclusions Children with ADHD+ASD experienced longer delays to treatment initiation and more frequent medication switching compared with those with ADHD only. The effects of alternative ADHD medication options on key negative clinical outcomes appeared similar to those of methylphenidate. Clinical implications These findings suggest that, rather than recommending fixed first-line and second-line treatments for individuals with ADHD-ASD, clinical guidelines should emphasise appropriate training as well as prompt and individualised treatment based on a shared decision-making process.
Findings the Hub has extracted
Each claim below is labelled by its type of design and links back to this report.
- Intervention
- Pharmacological treatment of ADHD with various medications (methylphenidate as primary comparison, alternative medications studied), including timing of initiation and treatment switching patterns
- Population
- Children (<13 years) and adolescents (13-17 years) with incident ADHD diagnosis between 2007-2018 in Sweden; 24,117 with comorbid ASD, 79,830 with ADHD alone
Key finding
12-14% of youth with ADHD+ASD initiated treatment >12 months after diagnosis versus 7-8% with ADHD alone
M et al. · Europe PMC · 11 Aug 2026